Masimo
Medical technology company that develops, manufactures, and markets noninvasive patient monitoring products.
Launch date
Employees
Market cap
CAD8.2b
Enterprise valuation
CAD9.2b (Public information from Sep 2024)
Share price
$111.73 MASI
Neuchâtel Neuchâtel (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 1.1b | 1.2b | 2.0b | 2.0b | 2.1b | 2.2b | 2.4b |
% growth | 22 % | 8 % | 64 % | 1 % | 2 % | 6 % | 6 % |
EBITDA | 284m | 311m | 346m | 266m | 398m | 438m | 464m |
% EBITDA margin | 25 % | 25 % | 17 % | 13 % | 19 % | 20 % | 20 % |
Profit | 240m | 230m | 144m | 81.5m | 99.8m | 167m | 202m |
% profit margin | 21 % | 19 % | 7 % | 4 % | 5 % | 8 % | 9 % |
EV / revenue | 12.3x | 12.6x | 3.8x | 3.0x | 2.0x | 2.0x | 1.9x |
EV / EBITDA | 49.6x | 50.3x | 22.5x | 23.3x | 10.8x | 10.4x | 9.4x |
R&D budget | 119m | 137m | 191m | 175m | - | - | - |
R&D % of revenue | 10 % | 11 % | 9 % | 9 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | - | ||
N/A | N/A | IPO | |
$5.0m | Grant | ||
N/A | Post IPO Equity | ||
* | N/A | $750m | Post IPO Equity |
Total Funding | CAD6.8m |
Related Content
Recent News about Masimo
EditInvestments by Masimo
EditACQUISITION by Masimo Mar 2020
ACQUISITION by Masimo Mar 2012
ACQUISITION by Masimo Feb 2022
ACQUISITION by Masimo Apr 2023
ACQUISITION by Masimo Nov 2020